The latest announcement is out from OKYO Pharma Limited Sponsored ADR ( (OKYO) ).
On March 31, 2025, OKYO Pharma announced that its drug urcosimod, currently in a Phase 2b clinical trial for neuropathic corneal pain, has demonstrated long-term stability in single-use ampoules for over two and a half years. This stability is a crucial step in meeting FDA requirements for drug approval, addressing shelf stability concerns. The successful stability results are expected to positively impact the company’s efforts to secure a New Drug Application with the FDA, enhancing its positioning in the biopharmaceutical industry.
More about OKYO Pharma Limited Sponsored ADR
OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuropathic corneal pain (NCP) and dry eye disease (DED). The company is listed on the NASDAQ Capital Market and is engaged in the discovery and development of novel molecules to treat these ocular conditions, with a significant market focus on the multi-billion-dollar dry eye disease market.
YTD Price Performance: 19.47%
Average Trading Volume: 194,290
Technical Sentiment Signal: Sell
Current Market Cap: $45.75M
See more data about OKYO stock on TipRanks’ Stock Analysis page.